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Abstract: We report the histopathology of epithelial overgrowth in the Boston type I kerato-
prosthesis. The epithelium shows an inconsistent number of layers and basement membrane 
and goblet cells are absent. Epithelialization of the keratoprosthesis optic would have multiple 
advantages, but the limitation of vision makes tolerating the overgrowth difficult.
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To the editor
The Boston Keratoprosthesis (KPro) was approved in 1992 by the US Food and Drugs 
Administration as a means to rehabilitate corneal blindness in eyes that are poor can-
didates for traditional penetrating keratoplasty.1 Failed corneal graft is the mainstay 
indication for KPro implantation, but some have advocated expanding the clinical 
indications to include pediatric corneal opacities,2 limbal stem cell deficiency,3 severe 
ocular trauma,4 and herpes zoster keratitis.5 Composed of poly(methyl methacrylate) 
(PMMA), the KPro has demonstrated good biocompatibility with corneal stroma, but 
there are limited data on the biocompatibility of the KPro with corneal epithelium 
and endothelium.6
Reported complications of the KPro include retroprosthetic membrane, infectious 
and sterile endophthalmitis, corneal melt, extrusion, and retinal detachment.7–9 In 
one series, 44% of eyes had retroprosthetic membrane requiring yttrium aluminium 
garnet membranectomy, 38% had a persistent epithelial defect requiring lateral tar-
sorrhaphy, 18% had elevated intraocular pressure, and 16% had corneal melt.10 We 
have noted epithelial growth over the KPro optic in some of our patients, and we are 
not aware of previous reports describing this occurrence or its incidence. We report a 
case of recurrent epithelial growth over the Boston KPro optic that degraded vision 
and provide histopathology analysis.
Case description
History
A 39-year-old male with a history of renal transplantation had subsequent 
cytomegalovirus retinitis in both eyes while on immunosuppression and also herpes 
zoster ophthalmicus in his left eye. He developed corneal scarring, and over the course 
of 9 years, he rejected four full-thickness corneal transplants in the left eye. In 2006, 
he underwent an uncomplicated implantation of an aphakic type 1 KPro. He remained Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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stable through 2009 with 20/70 best-corrected visual acuity, 
but in early 2010, he developed an epithelial growth over 
the optic of the KPro that caused his vision to deteriorate 
to 20/400. The epithelium was removed with a moistened 
cotton-tip applicator at the slit lamp, and his vision promptly 
returned to 20/70. A bandage contact lens was placed over the 
eye, and the patient was continued on topical antibiotics.
examination
Ten days later he returned with 20/300 vision in the left eye. 
External examination was within normal limits. Slit lamp 
examination showed a white and quiet conjunctiva. The 
cornea was quiet without necrosis or melt. There was no 
extrusion of the KPro, but epithelial regrowth over the KPro 
optic was noted (Figure 1). The anterior chamber was quiet 
without evidence of a retroprosthetic membrane.
Intervention treatment
The recurrence was managed under a surgical microscope 
using a 15° blade to scrape the epithelium completely off the 
optic. A bandage contact lens was placed over the KPro.
Pathology
A piece of tissue measuring 1.0 × 0.8 × 0.3 mm was submitted 
in formalin. The tissue was embedded into a paraffin block 
and sectioned with 5-µ cuts. The cuts were fixed to glass 
slides and stained with either standard hematoxylin and eosin 
or standard periodic acid–Schiff (PAS) preparation. Specimen 
slides revealed a nonkeratinized epithelium that was folded 
upon itself (Figure 2). The epithelium was composed of 3–5 
layers of cells, variable in each area of the slide. No dysplas-
tic nuclei or pleomorphic cells were noted, and epithelium 
matured normally. No basement membrane or goblet cells 
were noted with PAS staining.
Follow-up
The patient maintained 20/70 vision for the next 5 months 
without recurrence of the epithelial overgrowth. In June 2010, 
he complained of deteriorating vision to 20/300, and epithelial 
growth over the optic was noted and managed in the same 
fashion.
Discussion
Pathology
Giant cells are frequently noted on the surface of 
PMMA intraocular lenses.11 Epithelial migration over 
PMMA devices is a rare occurrence due to the scarcity of 
corneal or conjunctival epithelial exposure to implantable 
ophthalmic devices. Epithelium secretes basement membrane 
in order to adhere or migrate to a surface. With a lack of 
basement membrane on the specimen and the tight epithelial 
adherence to the PMMA KPro, we surmise that the epithe-
lial basement membrane may have incorporated within the 
PMMA material.
The histopathology of the scraped epithelium shows no 
goblet cells, which points toward a corneal epithelial origin. 
In addition, there are no blood vessels, which is likely due to 
the lack of inflammatory impetus. The epithelial sheet shows 
a varying, inconsistent number of cell layers, which limited 
the patient’s visual acuity.
Literature review
Ament et al6 studied the in vitro interaction between an immor-
talized human corneal–limbal epithelial (HCLE) cell line and 
PMMA, and they found that the PMMA was cytotoxic to the 
HCLE cells. In this report, we describe recurrent epithelial 
growth over the KPro PMMA optic in vivo that severely 
compromised the patient’s vision, and to our knowledge, this 
is the first description of this occurrence in the Boston Kerato-
Figure 1 slit lamp photograph of the type 1 Boston Keratoprosthesis with epithelial 
growth over the optic.
Figure 2 Hematoxylin and eosin stain of epithelial growth removed from the type 1 
Boston Keratoprosthesis optic surface showing a variable thickness and number of 
cell layers, no vascular structures, no goblet cells, and no basement membrane.Clinical Ophthalmology
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Type 1 Boston KPro with epithelial growth
prosthesis. This occurrence is not unusual in the management 
of KPro patients, but this topic has received little attention, 
despite the fact that it frequently hinders vision.
Outcome
Epithelial overgrowth is easily managed with scraping as 
described in this report. We recommend carrying the scraping 
beyond the edges of the optic to help prevent recurrence. 
A more definitive management may include use of antiprolif-
erative agents such as mitomycin C, but we have been hesitant 
to incorporate this measure because of the risk of melt.
Opinion
The corneal epithelium must be of uniform thickness to 
provide optical clarity. This case illustrates the ability of 
PMMA to support epithelial proliferation without the obtru-
sion of conjunctival goblet cells or vascularization. The key 
for successful epithelialization of the KPro optic is developing 
methods to guide the epithelium into a regular sheet of cells; 
thus, the vision would not be adversely affected, and the risk 
of infection and inflammation is minimized.
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